Brief: Antengene Announces Xpovio® Approved By The TGA In Australia For The Treatment Of Relapsed And/Or Refractory Multiple Myeloma And Triple Class-Refractory Multiple Myeloma
09/03/2022 10:57
March 9 (Reuters) - Antengene Corporation Ltd 6996.HK :
* ANTENGENE ANNOUNCES XPOVIO® APPROVED BY THE TGA IN
AUSTRALIA FOR
THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND
TRIPLE CLASS-REFRACTORY MULTIPLE MYELOMA
Source text for Eikon: ID:nPn3b9Klza
Further company coverage: 6996.HK
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106